Sen. Shelley Moore Capito Buys Eli Lilly and Company (NYSE:LLY) Shares

Senator Shelley Moore Capito (R-West Virginia) recently bought shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on November 04th, the Senator disclosed that they had bought between $1,001 and $15,000 in Eli Lilly and Company stock on October 24th.

Senator Shelley Moore Capito also recently made the following trade(s):

• Sold $15,001 – $50,000 in shares of International Business Machines (NYSE:IBM) on 10/29/2025.
• Sold $15,001 – $50,000 in shares of Microsoft (NASDAQ:MSFT) on 10/29/2025.
• Sold $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 10/22/2025.
• Sold $1,001 – $15,000 in shares of Lowe’s Companies (NYSE:LOW) on 10/21/2025.
• Sold $1,001 – $15,000 in shares of Paychex (NASDAQ:PAYX) on 10/21/2025.
• Sold $1,001 – $15,000 in shares of Lowe’s Companies (NYSE:LOW) on 10/20/2025.
• Sold $1,001 – $15,000 in shares of Chevron (NYSE:CVX) on 10/17/2025.
• Sold $1,001 – $15,000 in shares of Costco Wholesale (NASDAQ:COST) on 10/17/2025.
• Sold $15,001 – $50,000 in shares of Microsoft (NASDAQ:MSFT) on 9/18/2025.
• Sold $15,001 – $50,000 in shares of Apple (NASDAQ:AAPL) on 9/18/2025.

Eli Lilly and Company Stock Up 2.3%

Shares of NYSE:LLY opened at $927.48 on Thursday. The stock has a market cap of $876.82 billion, a P/E ratio of 60.62, a P/E/G ratio of 1.21 and a beta of 0.43. The firm has a fifty day moving average price of $792.03 and a 200 day moving average price of $773.89. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $955.46.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. During the same period in the previous year, the business posted $1.18 earnings per share. Eli Lilly and Company’s quarterly revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Sell-side analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be given a $1.50 dividend. The ex-dividend date is Friday, November 14th. This represents a $6.00 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is 29.35%.

Institutional Investors Weigh In On Eli Lilly and Company

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Wealth Preservation Advisors LLC purchased a new position in shares of Eli Lilly and Company in the first quarter valued at $27,000. Sumitomo Mitsui Financial Group Inc. acquired a new stake in Eli Lilly and Company in the 2nd quarter valued at about $27,000. Evolution Wealth Management Inc. purchased a new position in Eli Lilly and Company during the 2nd quarter valued at about $29,000. Steph & Co. raised its position in Eli Lilly and Company by 290.0% during the third quarter. Steph & Co. now owns 39 shares of the company’s stock worth $30,000 after acquiring an additional 29 shares during the last quarter. Finally, Financial Gravity Companies Inc. acquired a new position in Eli Lilly and Company during the second quarter worth about $31,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on LLY shares. HSBC lifted their target price on Eli Lilly and Company from $700.00 to $800.00 in a research note on Wednesday, October 1st. Hsbc Global Res upgraded shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research report on Wednesday, August 27th. DZ Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 14th. JPMorgan Chase & Co. reduced their price objective on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating for the company in a research report on Tuesday, September 16th. Finally, Guggenheim reiterated a “buy” rating and set a $948.00 target price on shares of Eli Lilly and Company in a research report on Thursday, October 16th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average price target of $940.00.

Insiders Place Their Bets

In other Eli Lilly and Company news, EVP Daniel Skovronsky acquired 1,000 shares of the company’s stock in a transaction dated Tuesday, August 12th. The stock was acquired at an average cost of $634.40 per share, with a total value of $634,400.00. Following the purchase, the executive vice president directly owned 137,660 shares in the company, valued at approximately $87,331,504. This trade represents a 0.73% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, Director Jamere Jackson acquired 200 shares of the business’s stock in a transaction that occurred on Friday, August 8th. The shares were bought at an average price of $639.56 per share, with a total value of $127,912.00. Following the completion of the transaction, the director directly owned 9,402 shares in the company, valued at approximately $6,013,143.12. The trade was a 2.17% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders acquired 4,514 shares of company stock valued at $2,894,841. Corporate insiders own 0.14% of the company’s stock.

About Senator Capito

Shelley Moore Capito (Republican Party) is a member of the U.S. Senate from West Virginia. She assumed office on January 3, 2015. Her current term ends on January 3, 2027. Capito (Republican Party) ran for re-election to the U.S. Senate to represent West Virginia. She won in the general election on November 3, 2020. Capito was first elected to the Senate in 2014, becoming the first female U.S. Senator in the state’s history. Prior to serving in the Senate, Capito was a member of the West Virginia House of Representatives from 1997 to 2001 and a member of the United States House of Representatives from 2001 to 2015. At the start of the 116th Congress, Capito was a member of the U.S. Senate committees on Appropriations, Commerce, Science, and Transportation, Environment and Public Works, and Rules and Administration. As of a 2014 analysis of multiple outside rankings, Capito is a more moderate right of center Republican Party vote. As a result, she may break with the Republican Party line more than her fellow members. Capito earned her bachelor’s degree from Duke University. After earning her M.Ed. from the University of Virginia, Capito was a college counselor and then director of an educational information center. She was the only Republican in the West Virginia congressional delegation until the 2010 elections and is the first Republican woman elected to Congress from West Virginia. Capito is a former chairwoman of the Congressional Caucus for Women’s Issues, as well as a member of the Congressional Arts Caucus. After an explosion responsible for the death of 29 coal workers, Capito founded the Congressional Coal Caucus. Prior to her election to the U.S. House, Capito served in the West Virginia House of Delegates.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.